The phase II acelERA study (ClinicalTrials.gov identifier: NCT04576455) compares the efficacy and safety of giredestrant with physician’s choice of endocrine monotherapy for ER+, HER2– breast cancer in the second or third line [113]. This evidence concerns the gene ESR1 and breast carcinoma.